Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 7/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7647993 | 0.85 | NAMPT (0.36) | MAPTTHRBKDM4EALDH1A1LMNA | |
| SCHEMBL8181127 | 0.77 | KMT2A (0.46) | HSD17B10MAPTPKMHTR1AHTR7 | |
| SCHEMBL8186473 | 0.76 | HTR2C (0.39) | ALDH1A1HTR1AHTR7HPGDRAB9A | |
| SCHEMBL7652613 | 0.75 | MEN1 (0.34) | MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL7966114 | 0.73 | KMT2A (0.53) | MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL8235601 | 0.68 | NAPRT (0.57) | NAPRTHSD17B10MAPTKDM4EALDH1A1 | |
| SCHEMBL10622054 | 0.66 | NAPRT (0.59) | NAPRTMAPTLMNA | |
| SCHEMBL30199134 | 0.66 | NAPRT (0.59) | NAPRTMAPTLMNA | |
| SCHEMBL28276127 | 0.66 | NAPRT (0.53) | NAPRTHSD17B10MAPTKDM4E | |
| SCHEMBL28154249 | 0.66 | NAPRT (0.53) | NAPRTHSD17B10MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6486173-B2 | SEROTONIN-7 (5-HT7); TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS SLEEP DISORDERS, DEPRESSION AND SCHIZOPHRENIA; FOR EXAMPLE 1,3-DIHYDRO-2-((4-(4-FLUOROPHENYL)-4-OXOBUTYL))ISOINDOLE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-26 | — | — | US | claimed |
| US-20010041714-A1 | 5-HT7 receptor antagonists | CAIN GARY A (US) | 2001-11-15 | — | — | US | claimed |
| US-6486173-B2 | SEROTONIN-7 (5-HT7); TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS SLEEP DISORDERS, DEPRESSION AND SCHIZOPHRENIA; FOR EXAMPLE 1,3-DIHYDRO-2-((4-(4-FLUOROPHENYL)-4-OXOBUTYL))ISOINDOLE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-26 | — | — | US | disclosed |
| US-20010041714-A1 | 5-HT7 receptor antagonists | CAIN GARY A (US) | 2001-11-15 | — | — | US | disclosed |
| US-6239143-B1 | TREATMENT CNS DISORDERS SUCH AS ANXIETY, DEPRESSION, SLEEP DISORDERS, AND SCHIZOPHRENIA. | DUPONT PHARMACEUTICALS COMPANY | 2001-05-29 | — | — | US | disclosed |
| WO-2000000472-A1 | 5-HT7 RECEPTOR ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041714-A1 | 5-HT7 receptor antagonists | HTR7, HTR5A, HTR1A | NAPRT 1159/4885HSD17B10 2715/4885MAPT 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.